Login
$ANNX
$3.61 +$0.04 (1.12%) After hours

$ANNX 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts

12 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026

10 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease

06 Aug 2026 8-K: Other Events

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

30 Jul 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of July 30, 2026 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability...

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Annexon, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 11, 2026. The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, wi...

07 May 2026 8-K: Results of Operations and Financial Condition

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA

30 Mar 2026 8-K: Results of Operations and Financial Condition

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA

17 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

14 Jan 2026 8-K: Regulation FD Disclosure

Exhibit 99.1 STOPPING NEUROINFLAMMATION AT ITS SOURCE TH 44 ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 2026 Nasdaq: ANNX ©2025 Annexon, Inc. All rights reserved

12 Jan 2026 8-K: Other Events

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026

14 Nov 2025 8-K: Entry into a Material Definitive Agreement; Other Events

25,096,153 Shares of Common Stock, par value $0.001 per share

10 Nov 2025 8-K: Results of Operations and Financial Condition

Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA)

14 Aug 2025 8-K: Results of Operations and Financial Condition

Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA

25 Jun 2025 8-K: Material Modification to Rights of Security Holders

This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT, dated as of June [•], 2025 (this “Amendment”), amends that certain COMMON STOCK PURCHASE WARRANT (the “Warrant”), dated as of July 11, 2022, by Annexon, Inc. (the “Company”) for the ...

09 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

Annexon, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 5, 2025. The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, wit...

12 May 2025 8-K: Results of Operations and Financial Condition

FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission

03 Mar 2025 8-K: Results of Operations and Financial Condition

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License Application (BLA) Submission

13 Jan 2025 8-K: Other Events

ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA Submission

10 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support